References
- GoldhaberSZBounameauxHPulmonary embolism and deep vein thrombosisLancet201237998281835184622494827
- HylekEMReganSHenaultLEChallenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosisArch Intern Med2003163562162712622610
- MartelNLeeJWellsPSRisk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysisBlood200510682710271515985543
- BüllerHRDavidsonBLDecoususHSubcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolismN Engl J Med2003349181695170214585937
- Hokusai-VTE InvestigatorsBüllerHRDécoususHGrossoMAEdoxaban versus warfarin for the treatment of symptomatic venous thromboembolismN Engl J Med20133691406141523991658
- PrandoniPLensingAWAPrinsMHResidual venous thrombosis as a predictive factor of recurrent venous thromboembolismAnn Intern Med20021371295596012484710
- PrandoniPLensingAWABernardiEThe diagnostic value of compression ultrasonography in patients with suspected recurrent deep vein thrombosisThromb Haemost200288340240612353067
- HisatakeSKabukiTKiuchiSShort-term subcutaneous fondaparinux and oral edoxaban for acute venous thromboembolismCirc J201781685586128239036
- KabukiTNakanishiRHisatakeSA treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolismJ Cardiol201770216316827979674
- FaulFErdfelderELangAGBuchnerAG*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciencesBehav Res Meth2007392175191
- JCS Joint Working GroupGuidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism (JCS2009). Japanese Circulation SocietyCirc J2011751258128121441695
- KearonCAklEAComerotaAJAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest20121412 Supple419Se496S22315268
- KearonCAklEADuration of anticoagulant therapy for deep vein thrombosis and pulmonary embolismBlood2014123121794180124497538
- ScheinJRWhiteCMNelsonWWKlugerJMearnsESColemanCIVitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequencesThromb J2016141427303213
- EINSTEIN InvestigatorsOral rivaroxaban for symptomatic venous thromboembolismN Engl J Med20103632499251021128814
- YamadaNHirayamaAMaedaHOral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE programThromb J201513225717286
- ZierlerBKUltrasonography and diagnosis of venous thromboembolismCirculation200410912 Suppl 1I9I1415051663
- FurugohriTIsobeKHondaYDU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profilesJ Thromb Haemost2008691542154918624979
- FukudaTTsujiNHondaYKamisatoCMorishimaYShibanoTComparison of antithrombotic efficacy between edoxaban, a direct factor Xa inhibitor, and fondaparinux, an indirect factor Xa inhibitor under low and high shear ratesThromb Haemost201110661062106821946952
- MorishimaYKamisatoCHondaYTreatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in ratsEur J Pharmacol2014742152125179572